ELTP Alerts 08/16/2014 11:30:03 $ELTP Unfortunately that

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
ELTP Alerts 08/16/2014 11:30:03 $ELTP
Unfortunately that is not true. Perhaps one should read the FDA approved statement:

The naltrexone component was shown to have degraded to unacceptable degrees in samples of Embeda that were tested, Pfizer said. The problem is unlikely to pose a safety risk and patients can continue taking the drug as prescribed, the drugmaker said.


Seems there are new partners involved now too. speculation is J&J as well as Actavis. Product is modular so you are looking at a several billion dollar buyout. This is the most likely end game with Elite. Just a matter of when it happens. The further along this goes, the higher the price goes.
Yes, because we were/are holding out until OUR terms are met. That way all shareholders get the best deal possible.
Why am I not surprised to hear complaints that Elite is growing and see's a need for expansion? Ooh the horror! They must be doing pretty poorly to need additional space? It's not like the company is in its strongest financial shape ever, it's not like the CEO, BOD, and employee's whom are compensated partially with shares care about the share structure. It's not like we are ramping up to enter a market worth BILLIONS, or have modular technology that once one ADT product is approved, others will follow in rapid succession.

Clearly, we should all sell and move to Houston, plant a couple pecan trees and wait for the nuts to arrive. ...if they are not already here.

Very Bullish $ELTP


Here's what people need to know when it comes to investing:


-Hindsight is 20/20.

-Long term investors ALWAYS outperform traders.

-Traders ALWAYS lose.

-The greatest investor of ALL TIME follows the long term approach.


Have a great day everyone.
No it's completely UN-predictable.

HINDSIGHT IS 20/20.

I've followed this message board for over 3 years and read every message and EVERYONE HAS BEEN COMPLETELY WRONG ABOUT EVERYTHING


Bad idea to buy, hold, accumulate if you are in penny stocks; good way of going broke. Good idea to flip ELTP because it really is so predictable.
Bad idea.

It's a proven fact you make more money by never selling.

Ask Warren Buffett - The greatest investor of all time.

Also, it's a proven fact that all females outperform all males when it comes to investing. WHY? - Because THEY NEVER SELL!!!!!!!!!

This is why I will never sell and is why I currently have and will continue to make more money than everyone on this board who trades!!!!!!!!!

It's a proven fact that traders underperform the market and underperform ELTP.

All who have tried to trade stocks ALWAYS GET BURNED.

Warren Buffett - "Our favorite holding period is FOREVER".
Hmmmmmmmm!!!!!!! It has been reloading time and now it is time to actively wait for flipping opportunity creation and the ceremonious dumping of shares in the rinse repeat fashion. This has been the most consistent thing about ELTP over the past 3 years. I too am waiting to activate my FlipperMe alias.
Remember last year at the R and R conference Nasrat said "there are a lot of partners".

Here we are 1 YEAR LATER, STILL NO PARTNERS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Quote:
partnership talks underway

Why do you care if a run is coming????

You said you were a long term investor.
The question was not that Isradipine existed or didn't exist. It was that it should have launched by now and didn't courtesy of CEO who believes generics are bread crumbs but yet dumped 12 of the bread crumb producers on JT for a hefty $10M. No wonder CEO does his best to hype ELTP with his substantiated and undocumented protocols for evaluations, his own, and the mysterious evaluation company.

I do sense that hype is losing its edge; it is not producing like before. Wonder why? Could it be the millions upon millions of new shares in the A/S. I am told that there are 995,000,000 shares. Complicating this fact is the new "oh by the way" there is a 20,000sf addition in the pipeline that could cost millions more in shares. The irony is that Elite already has two facilities which were supposed to accommodate the ART; that 11 ANDA generics were farmed out to Epic. Incidentally the one not farmed out is the one that Elite said it couldn't produce then decided in could produce and hasn't produced to date.
Indeed good sir.....yes indeed Elite has come along way and the DD Longs saw what was coming from a long ways away and let no disturbance detract from gathering shares on the cheap. You and I both know the next run is gearing up and is coming.....you have picked up additional shares recently and I am playing the Bear Raid and sell the news mentality.

This is why you pick up shares below .35.....yes indeed the RUN is coming and we both know it!! $$$$$
Quote:
1) Pursuant to the terms and conditions of the Modified 135 Ludlow Lease, the Company is permitted to use the entire 35,000 square feet in the building located at 135-137 Ludlow Avenue for the storage of pharmaceutical finished goods, raw materials, equipment and documents as well as engaging in manufacturing, packaging and distribution activities.

Prior to the Modified 135 Ludlow Lease, the Company occupied only 15,000 square feet at the 135 Ludlow location. The Modified 135 Ludlow Lease accordingly represents a significant expansion in the size of the Northvale Facility.

2) Research and development costs for the three months ended June 30, 2014 were $4,020k, an increase of $3,451k or approximately 607% from $238k of such costs for the comparable period of the prior year. The increase was primarily due to increased activities related to the development of Elite’s abuse resistant opioid products.

3) The Company believes that the successful resolution of the monetary bond defaults will have a significant and positive effect on the Company’s operations.

Yes that does sound quite familiar. Good thing I listened to my gut just like I am now.

No more going concern, bond debt issue gone, partnership talks underway, NDA on track to be filed by years end....
Yeah just like ELTP was no good at .125 and the Mountain of cries for selling came and went like a hill of manure.
LMAO "If they exist at all" ....thats a good one.....so what is going to be said when Isradipine is launched??? Heard the same misinformation when the stock was at .06 and Elite was waiting on Methadone to launch.

Problem is all the antihype is being left in the dust. No more going concern and clearing up the bond debt issue.
Quote:
The significant increase in revenues is due to the continued growth and expansion of Elite’s generic product lines

Please do tell. What is happening on all the opioids besides being acclaimed into the pipeline. Yes I know, they are just in the pipeline.
Noticed that the revenue clip was removed and probably for good reason. There is not much there compared to the expenditures and we don't want to call attention to that. We also didn't mention the potential of additional dilution to pay for the dream 20,000sf addition that is designed to produce the 11 ANDAs that Epic will be doing for the substantial cut nor does it say what the current facilities, intended to take care of generics and ART, will be dedicated to. Oh don't say, they will continue producing the 8 generics.
Oh! Is there doubt? Should there be after all CEO said so! CEO said $5.00 then it must be $5.00.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Biohaven's BHV-1530 Data Earns a Careful Investor Look

Updated Category News Views 19

Thirty heavily treated cancer patients can make a molecule look brilliant or merely lucky, and BHV-1530 is still living in that uncomfortable early-stage gap. Biohaven presented Phase 1 results at ENA 2026 that deserve real attention, particularly because the responses showed up in patients with few attractive remaining options. But this is not the moment to confuse a...

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 66

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 21

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Tongwei's 846 MW Romania Deal Tests Solar Supply Scale

Updated Category News Views 74

Eight hundred forty-six megawatts of panels do not quietly roll out the factory gate. Tongwei’s supply agreement with Rezolv Energy for Romania’s Dama Solar project is a hefty piece of utility-scale solar business, and the first truckload has already left Tongwei’s Nantong facility. That matters more than another polished signing-ceremony photo: equipment is moving,...

Continue Reading
NVE Revenue Pull-Forward Raises Hard Investor Questions

Updated Category News Views 50

A Quarter Can Look Great Until It Doesn’t NVE investors got a nasty lesson in revenue timing, the sort that makes even old hands check the fine print twice. On July 22, 2026, the company reported sequential revenue growth of 43% and net-income growth of 23%. The next trading day, shares vaulted $47.53, or 54%. Then came October, and the floor gave way: NVE reported that...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 87

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 31

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 49

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 101

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 217

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading

Top 5 Most Recently Viewed Articles

commercetools Compilations: Innovations Driving Digital Growth

Updated Category News Views 177

Exciting Launch of commercetools Compilations commercetools has unveiled Compilations, a semi-annual showcase that highlights more than 50 product enhancements, demonstrating the organization’s dedication to innovation and improved customer experiences for users of the commercetools Platform. With over 13,000 deployments and 200 releases, this initiative significantly...

Continue Reading
Join the Class Action Against Red Cat Holdings, Inc. Today

Updated Category News Views 185

Understanding the Class Action Against Red Cat Holdings, Inc. Red Cat Holdings, Inc. is currently under the spotlight due to a class action securities lawsuit filed by the law firm Levi & Korsinsky, LLP. The firm is reaching out to investors who believe they have incurred losses due to the alleged securities fraud that transpired between a specified period. If you have...

Continue Reading
GRAIL Initiates Patient Testing with Innovative Blood Test for Lung Cancer

Updated Category News Views 127

GRAIL Announces Milestone in Lung Cancer Detection GRAIL, Inc. (Nasdaq: GRAL), a pioneering healthcare firm focused on early cancer detection, has achieved a significant milestone by announcing that the first patient has been assessed for eligibility through its innovative non-small cell lung cancer (NSCLC) ctDNA Assay. This groundbreaking development occurs within the...

Continue Reading
Neurocrine Biosciences Enhances Collaboration with Takeda

Updated Category News Views 197

Neurocrine Biosciences Enhances Collaboration with Takeda Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has recently announced an amendment to strengthen the strategic collaboration with Takeda. This partnership focuses on the development and commercialization of osavampator, an innovative therapeutic candidate that holds promise for patients suffering from major depressive...

Continue Reading
LivaNova Prepares to Reveal 2024 Year-End Financials

Updated Category News Views 94

LivaNova's Upcoming Financial Announcement LivaNova PLC (Nasdaq: LIVN), a prominent player in the medical technology sector, is gearing up for an important event. The company will hold a conference call in which they will discuss their financial results from the fourth quarter as well as the entire year of 2024. This event is slated for a Tuesday afternoon and is expected...

Continue Reading